AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Breast cancer survivors have a lower risk for heart attacks.
2003 JUN 19 - (NewsRx.com & NewsRx.net) -- Elderly women who have survived early-stage breast cancer are significantly less likely to have an acute myocardial infarction (AMI) than women who do not have histories of breast cancer, according to a new study.
The authors discovered that women who have at least one baseline risk factor for coronary artery disease experience the most significant reduction in risk for an AMI.
They conclude in the July 1, 2003, issue of Cancer, "We have identified a subset of women who have one-third reduction in the disease that accounts for the largest number of deaths in elderly women in the United States." They suggested, "Further work might elucidate the mechanism behind this risk reduction in breast cancer and be leveraged to improve the cardiovascular health of the general population."
The presence of estrogen in the body has been shown to be both detrimental and beneficial. Too much is protective against osteoporosis and heart disease (i.e., estrogen is implicated in the 10-year delay in onset of heart disease that women experience relative to men) but contributes to breast and endometrial cancers. Too little is protective against breast cancer but contributes to osteoporosis and heart disease (e.g., increased cardiac risk of women with premature menopause). Modulation of estrogen is the basis behind the therapeutic effects of selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, in treating breast cancer.
SERMs act like estrogens in certain organs and act like antiestrogens in other organs. As such, SERMs may also be relevant to other estrogen-sensitive conditions such as heart disease. A few clinical trials of SERMs in early-stage breast cancer have reported a 30-48% decrease in AMIs among women treated with SERMs compared to placebo. A recent trial of SERMs in women without a history of breast cancer showed a 40% decrease in AMIs.
Taking this information together, the authors hypothesized that from high estrogen exposure that contributed to the development ...
- Reduced Cardiac Risk for Breast Cancer Survivors.
- Newspaper article from: Clinical Oncology Alert August 1, 2003 700+ words
Reduced Cardiac Risk for Breast Cancer Survivors Abstract...effect was stronger in breast cancer survivors with documented cardiac risk factors. Lamont et...this reduction in cardiac risk in breast cancer survivors, the finding...
- Breast cancer survivors have a lower risk for heart attacks.
- Newspaper article from: Cardiovascular Week June 16, 2003 700+ words
...analysis of baseline cardiac risk and breast cancer history showed that...declined 50% among breast cancer survivors with one cardiac risk factor compared...with no history of breast cancer and one cardiac risk factor. Lamont...
- Study Compares DOXIL(R)/CAELYX(R) (Doxorubicin HCL Liposome Injection) to...
- Press release article from: PR Newswire May 20, 2004 700+ words
...particularly relevant for patients with metastatic breast cancer who are at increased cardiac risk, such as the elderly, or patients with specific...Zealand). * Involved women with metastatic breast cancer (stage IIIB or IV) who were randomized to...
- Take steps to protect your heart during cancer treatment: women with breast...
- Magazine article from: Heart Advisor October 1, 2008 700+ words
Deaths from breast cancer have decreased by 24 percent...Many women are surviving breast cancer, only to develop severe...risk of heart damage from breast cancer treatment, make sure any cardiac risk factors are under control...
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients...
- Press release article from: PR Newswire June 3, 2007 700+ words
...select metastatic breast cancer patients who are at increased cardiac risk." The current...CAELYX in metastatic breast cancer is 50 mg/m2...for metastatic breast cancer in patients who are increased cardiac risk. CAELYX is also...
- CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in First-Line...
- Press release article from: PR Newswire March 11, 2004 700+ words
...treatment of metastatic breast cancer represent an important advance...treatment of metastatic breast cancer in women who are at cardiac risk. CAELYX also is marketed...509 women with metastatic breast cancer were randomised to receive...
- S-P's Caelyx increases TTP in breast cancer.(Schering-Plough...
- Newspaper article from: Pharma Marketletter June 11, 2007 700+ words
...time-to-progression in patients with metastatic breast cancer. The announcement was made at the annual American Society...that the drug was safe and effective for metastatic breast cancer patients who are at increased cardiac risk.
- Schering-Plough Announces EU Approval of CAELYX(R) in Metastatic Breast Cancer.
- Press release article from: PR Newswire January 14, 2003 700+ words
...monotherapy for metastatic breast cancer in patients who are at increased cardiac risk. Commission approval...visceral disease. In the breast cancer clinical registration...to treat metastatic breast cancer. Additionally, CAELYX...